anti-IL-33 (human), mAb (IL33305B)
| Code | Size | Price |
|---|
| AG-20A-0041-C050 | 50 ug | £217.00 |
Quantity:
| AG-20A-0041-C100 | 100 ug | £314.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG2aκ
Antibody Clonality: Monoclonal
Antibody Clone: IL33305B
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Functional Study
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Shipping:
Blue Ice
Storage:
-20°C
Further Information
Alternate Names/Synonyms:
Interleukin-33; IL-1F11; NF-HEV
Concentration:
1mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. 0.2µm-filtered solution in PBS, pH 7.4. Contains no preservatives.
Handling Advice:
After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.
Immunogen:
Recombinant human IL-33.
Long Description:
Monoclonal Antibody. Recognizes human IL-33. Does not cross-react with mouse IL-33. Isotype: Mouse IgG2akappa. Clone: IL33305B. Applications: ELISA, FUNC (Blocking), IHC, IP, WB. Liquid. 0.2µm-filtered solution in PBS, pH 7.4. Contains no preservatives. Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30kDa human IL33 is converted by CASP1 to a 18kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.
NCBI, Uniprot Number:
O95760
Package Type:
Plastic Vial
Product Description:
Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30kDa human IL33 is converted by CASP1 to a 18kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.
Specificity:
Recognizes human IL-33. Does not cross-react with mouse IL-33.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
References
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis: G. Palmer, et al.; Arthritis & Rheum. 60, 738 (2009) | Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease: J. Chapuis, et al.; Mol. Psychiatry 14, 1004 (2009) (Supplement Information) | Interleukin-33 is biologically active independently of caspase-1 cleavage: D. Talabot-Ayer, et al.; JBC 284, 19420 (2009)
Related Products
| Product Name | Product Code | Supplier | IL-33 (human) (rec.) (His) | AG-40A-0042 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|